Living

UK's GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion

By Reuters Reuters
FILE PHOTO: Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo
FILE PHOTO: Signage is pictured in the main lobby of GSK offices in London, Britain, February 20, 2025. REUTERS/Chris J. Ratcliffe/File Photo Chris J Ratcliffe Reuters

British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio.

The all-cash deal values Nuvalent at approximately $124 per share, a 40% premium to its last closing price.

(Reporting by DhanushVignesh Babu and Yadarisa Shabong in Bengaluru; Editing by Mrigank Dhaniwala)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 9, 2026 at 1:18 AM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER